




Supplementary information, Figure S4

(a) Schematic map of the CRISPR Knock-In process. **(b)** RNA expression of *OLMALINC* in HEK-293T, GES-1, HeLa, AGS, and MKN45 cells. Data were presented as mean $\pm$ SEM. **(c)** RNA expression of *TRHDE-AS1* in HEK-293T, GES-1, HeLa, AGS, and MKN45 cells. Data were presented as mean $\pm$ SEM. **(d)** RNA expression of *ZNF436-AS1* in HEK-293T, GES-1, HeLa, AGS, and MKN45 cells. Data were presented as mean $\pm$ SEM. **(e)** RNA expression of *AC027045.3* in HEK-293T, GES-1, HeLa, AGS, and MKN45 cells. Data were presented as mean $\pm$ SEM. **(f)** Clone formation assay of wildtype (WT), pep1-nc-OLMALINC knockout (KO), pep1-nc-OLMALINC knockout with wildtype ORF back-complemented (Rescue), and pep1-nc-OLMALINC knockout with start codon mutant ORF back-complemented (Mutant) AGS cells. **(g)** Clone formation assay of wildtype (WT),

pep-nc-ZNF436-AS1 knockout (KO), pep-nc-ZNF436-AS1 knockout with wildtype ORF back-complemented (Rescue), and pep-nc-ZNF436-AS1 knockout with start codon mutant ORF back-complemented (Mutant) AGS cells.